Header graphic for print
LimeGreenIP News

Tag Archives: pharmaceutical patents

The skilled machines disrupting drug design

Capable of identifying novel compounds for therapeutic use, AI is saving time and costs in a process that can take around 10 to 15 years and billions of pounds to complete. For the pharmaceutical industry, which has traditionally relied on patents to protect innovation and fund R&D, this should be good news, but is an

Looking ahead at AI’s effect on IP in the pharma sector

In April’s issue of Pharma Times Magazine, partner Cullen Taylor explores how new machine learning technologies may have far-reaching, unexpected effects on IP and patent law. Cullen’s article looks at how AI is likely to accelerate the process of developing drugs and identifying patients who can benefit from them. It outlines patentability challenges for policy makers as well

U.S. – What does the Impression Products v. Lexmark decision mean for drug companies? 5 takeaways

Last May, the U.S. Supreme Court issued a highly-anticipated decision in Impression Products, Inc. v. Lexmark Int’l, Inc., reversing the Federal Circuit and holding that, when a patent holder sells a product, it exhausts all of its patent rights in the product, regardless of certain restrictions that the patent holder sought to impose on further resale.

Major IP reforms foreshadowed in China’s Pharma sector.

On 12 May 2017, the Chinese Food and Drug Administration (the “CFDA”) issued several draft policies aimed at overhauling of the current regulations governing the Chinese pharma and medical device sector (the “Draft Policies”). Amongst the Draft Policies, those outlined in Circular No.55 would, if implemented, establish a more robust patent linkage system, a more

Italian time-machine : Limitation of the duration of an SPC may be decided by the Italian Patent Office

The Board of Appeal of the Italian Patent Office (Commissione dei Ricorsi), by decision published on June 26, 2017, acknowledged the right of the patent holder to ask the Italian Patent Office for the limitation of the duration of a supplementary protection certificate (SPC) further to its recalculation on account of an earlier marketing authorisation. Background

New on LimeGreen IP Knowhow: SPCs for pharmaceutical products – a European guide

We’ve added a new topic to Hogan Lovells’ LimeGreen IP: focused on guiding you through the regulatory regime governing Supplementary Protection Certificates  in Europe. SPCs have for many years proved a fertile area for dispute. This is due to a number of factors including: lack of clarity in the governing legislation; the evolution of new types of medicines leading to questions

US: Pharma-friendly trends at USPTO and PTAB

Recent USPTO activity may signal a shift in treatment of pharmaceutical patents in AIA proceedings. The America Invents Act (“AIA”) provides for adversarial proceedings for challenging patents in the United States Patent and Trademark Office (“USPTO”) — including inter partes review (“IPR”) and post grant review (“PGR”) — which are faster, cheaper, and have a lower